- Home
- DNTH vs ECAT Comparison
DNTH vs ECAT Comparison
Compare DNTH & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DNTH | ECAT |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DNTH | ECAT |
|---|---|---|
| Price | $42.09 | $15.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $68.00 | N/A |
| AVG Volume (30 Days) | ★ 678.9K | 278.6K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.20% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.39 |
| Revenue | ★ $3,078,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.37 | $14.02 |
| 52 Week High | $45.46 | $17.30 |
Technical Indicators
Market Signals| Indicator | DNTH | ECAT |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 43.35 |
| Support Level | $42.02 | $15.53 |
| Resistance Level | $44.00 | $15.67 |
| Average True Range (ATR) | 1.76 | 0.17 |
| MACD | -0.27 | -0.00 |
| Stochastic Oscillator | 46.85 | 19.51 |
Price Performance
Historical ComparisonAbout DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.